Focus: Candel Therapeutics is a public biotech focused on oncolytic viral immunotherapies for solid tumors across oncology indications. The company is headquartered in Needham, MA and operates as a clinical-stage development company with a diversified pipeline.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Candel Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Candel Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Candel Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Two new Candel hires get options to buy 29,400 shares at $6.18 - Stock Titan
Two new Candel hires get options to buy 29,400 shares at $6.18 Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch - Yahoo Finance
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch Yahoo Finance
Candel picks EVERSANA over building its own sales force for prostate launch - Stock Titan
Candel picks EVERSANA over building its own sales force for prostate launch Stock Titan
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer - Sahm
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer Sahm
BlackRock files Schedule 13G/A reporting 3,079,861 CADL shares (NYSE: CADL) - Stock Titan
BlackRock files Schedule 13G/A reporting 3,079,861 CADL shares (NYSE: CADL) Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo